#treatment of coronavirus

[covid-safer-hotties]

Also preserved in our archive (Daily updates!)

By Mary Van Beusekom, MS

New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.

Benefit seen only in older patients For the first study, published in Clinical Microbiology and Infection, a Medical University of Vienna–led research team compared the effectiveness of Paxlovid with that of the antiviral drug molnupiravir (Lagevrio)—and with that of not receiving an antiviral—against hospitalization and all-cause death from January 2022 to May 2023. Participants were adults with mild to moderate infections and one or more risk factors for severe illness caused by the SARS-CoV-2 Omicron variant.

"The oral antivirals nirmatrelvir-ritonavir and molnupiravir are the mainstay treatment for Covid-19 in non-hospitalised adults at increased risk of severe disease," the study authors wrote. "Both oral antivirals were approved at the time of the study period (2022/2023) for the treatment of non-hospitalised patients with mild-to-moderate Covid-19, but the current National Institute of Health guidelines favour nirmatrelvir-ritonavir over molnupiravir."

Of the 113,399 eligible COVID-19 patients in the retrospective cohort study, 10.7% received Paxlovid, 9.5% received molnupiravir, and 80.0% served as untreated controls. Over 96% of participants were previously infected with or vaccinated against COVID-19.

A total of 0.43% of Paxlovid recipients, 1.4% of molnupiravir users, and 1.13% of controls were hospitalized within 28 days (risk difference [RD], -0.7%; Paxlovid vs control RD, 0.26%). No Paxlovid recipients and 0.13% each of molnupiravir users and controls died.

The estimated risk of hospitalization was 0.57% in Paxlovid users and 1.09% in controls (adjusted RD [aRD], -0.53%). The estimated risk of death was 0.0% in the Paxlovid group and 0.13% in controls (aRD, -0.13%).

The number of patients needed to treat to prevent hospitalization and death was 190 in Paxlovid recipients and 792 in controls, respectively. These statistically significant aRDs were seen only among patients 60 years and older.

The estimated risk of hospitalization in the molnupiravir analysis was 1.36% in the molnupiravir group and 1.16% among controls (aRD, 0.2%). The estimated risk of death was 0.12% in molnupiravir recipients and 0.14% in controls (aRD, -0.01%).

"Among outpatients aged ≥60 years with Covid-19 in an Omicron-dominated era, treatment with nirmatrelvir-ritonavir was associated with a lower risk of hospitalisation and all-cause death within 28 days, albeit with wide confidence intervals and high numbers needed to treat," the study authors wrote.

"This finding was not observed in molnupiravir users and younger nirmatrelvir-ritonavir users. Future studies are needed to better define target populations that show greater benefit from treatment with nirmatrelvir-ritonavir," they concluded.

Proportion of patients seeking care slashed 73% The second study, a phase 2/3 randomized clinical trial published today in Clinical Infectious Diseases, also found protection against COVID-19 hospitalization and death in adults receiving Paxlovid and demonstrated a faster resolution of symptoms and lower use of healthcare resources compared with a placebo in high-risk patients.

The research was led by researchers from Pfizer, which developed Paxlovid. The drug was given to 977 symptomatic COVID-19 patients, while 989 were given a placebo, at 343 sites in 21 countries from July 2021 through December 2021, a Delta-predominant period.

Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio, 1.27) and resolution (16 vs 19 days; HR, 1.20) through 28 days and cut the number of COVID-related medical visits by 64.3% and the proportion of patients seeking care by 73.2%.

In total, 0.9% of Paxlovid recipients and 6.4% in the placebo group were hospitalized, for a relative risk reduction of 85.5%. Hospitalized Paxlovid recipients had briefer hospital stays, and none required intensive care or mechanical ventilation. Fewer patients in the Paxlovid group needed other COVID-19 treatments, and none died by 6 months, compared with 15 in the placebo group.

"The importance of having effective COVID-19 treatments such as NMV/r [Paxlovid] to reduce burden on healthcare systems, both ambulatory and hospital based, should not be underestimated," the authors wrote.

Study Links: www.clinicalmicrobiologyandinfection.com/article/S1198-743X(24)00508-1/fulltext

academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae551/7889107

[gumjrop]

Masking and Protests

In a win for community care,masks are being used broadly at recent protests on college campuses across the country, making these protests more accessible as well as showing solidarity with disabled communities. Some college campuses have attempted to ban or discourage masking at protests. University of Texas at Austin’s Provost issued a statement including a rule banning masks, and University of North Carolina’s Provost asked protestors not to mask, citing a state law from 1953 enacted in response to the KKK. Notably, the North Carolina mask law contains an amendment, introduced in 2020, to allow masking “to ensure the physical health or safety of the wearer or others” (see PDF link to the amendment).

Masking at protests must be allowed to make protests accessible for disabled and immunocompromised people, and safer for everyone. COVID and other infectious diseases can spread both indoors and outdoors, especially in crowded settings. Share our guide to accessible protests on Instagram or Substack, and also check out our statement and call to action on Palestine. Also consider supporting mask distribution efforts such as local mask blocs, which may be seeing increased demand related to protests.

Wins

Remember our allies at the University of California Academic Worker Union from our January 2023 webinar, who fought for COVID safety protections? They're running for office this week on the executive board of UAW local 4811.  Check out their slate—which includes disability justice and COVID protections—and learn how to vote here.

The Weather

The CDC’s reported COVID wastewater levels by state show “Low” or “Minimal” wastewater levels across all reporting states and territories as of April 25, with no data available from North Dakota, West Virginia, Puerto Rico, the US Virgin Islands, and Guam.

Wastewater levels across all four regions are at lower levels than this year’s fall-winter peaks, with all regions showing either a slowing of the rate of decrease or a leveling off. You can still be infected during times of lower wastewater COVID levels. Precautions including consistent masking in all public spaces are still necessary in our daily lives to reduce the risk of infection, to prevent Long COVID, and to practice community care.

Variants

The CDC’s variant tracking has been updated and now shows many JN.1 sublineages, including KP.2, JN.1.7, and JN.1.13.1. Regional variant NowCast predictions are not available as of April 26 for any US region.

COVID Treatment

With the end of the national Test to Treat program in mid-April, we have lost an important route for affordable and convenient access to Paxlovid. Still, Paxlovid continues to be an important treatment to prevent the development of severe COVID. A few important facts about Paxlovid eligibility that people may not be aware of:

Paxlovid can be started within 5-7 days of the start of COVID symptoms. Initially, starting within 5 days was the recommendation. The extended window for treatment is particularly important as folks may test positive later in the course of their infection, sometimes a few days after symptoms develop. 

People aged 50 and older are eligible even if they do not have other medical conditions.

Younger people with certain medical conditions may also be eligible for Paxlovid.

The PAXCESS program may provide a Paxlovid discount from the manufacturer and provides free Paxlovid for people who receive Medicare or Medicaid and uninsured people without prescription drug benefits. 

If you are infected with COVID, make sure you also talk with your doctor about over-the-counter medications or supplements you may be taking. Even over-the-counter medications can have significant risks that should be discussed in the context of your individual medical history.

COVID Prevention

An effective multilayered approach to COVID prevention should include proven measures such as masking with high-quality respirators (N95s, KN96s, KF94s or better), improving indoor air quality with ventilation and filtration, physical distancing, getting the latest vaccines, and using COVID tests appropriately. Unproven methods should not be considered part of a multilayered approach. Topical nasal products such as sprays or ointments may seem tempting but are not proven to prevent COVID infections (none are FDA approved for COVID) and may have risks. For example, Vaseline and petrolatum-based ointments can cause pneumonia if applied to the inside of the nose, as they may be subsequently inhaled where they can damage the lungs. Over-the-counter antibiotic ointments are intended to protect from bacterial infection in minor skin wounds and should not be used inside the nose. Although early research on other uses has been publicized, given the risks of petrolatum-based ointments if used in the nose, it is important to wait for larger scale studies to understand both potential risks and benefits. Colloidal silver, sometimes touted in nasal spray form, is not proven to treat or prevent any medical condition and can cause permanent gray pigmentation of the skin as well as other serious side effects. Research studies shared in the news or on social media should not be used in place of medical advice from an individual healthcare provider you trust. 

While we expect masking and other multilayered precautions to remain a mainstay of prevention, we hope that further research will lead to FDA-approval/authorization of additional drugs for COVID treatment and prevention in the future.

Measles

Measles outbreaks within the US continue, with the first Wisconsin case being reported. Measles transmits through the air as well as through contact with surfaces, and is highly contagious. Now is a good time to check vaccination records for yourself and your loved ones, get any catch-up vaccinations, and check with your local healthcare provider if you are uncertain about vaccination or immunity status. In some cases, lab testing for measles immunity (antibody titers) can be helpful.

Take Action

Use MaskTogetherAmerica’s letter campaign to ask your elected officials to reinstate the Test to Treat program for free and convenient COVID and influenza testing, telehealth, and treatment access.

Support science-based COVID isolation guidance from the CDC using our letter campaign to contact your elected officials or sign on to our expert letter.

If you know someone who is organizing a protest, share our guide to accessible protests with them, via Instagram or Substack.

[thehiddenworld]

Covid 19 wasn't enough

 Covid 19 wasn't enough so besides the train derailments contaminating water, factories burning down they now invented a fungal that is not curable by antibiotics or any kind of medication. 

The fungal is called Candida auris or C. Auris. They are saying it is a yeast type of fungus that is spreading through health care facilities.

 Apparently it was only in 3 states back in 2016 but has spread to 20-27 states in 2022 but now is in 30 states.

 Why are they just now sharing this? Why are they just now talking about it now that the Covid has died down and no longer causing a panic?

This is probably to lead to another panic and pandemic as if the train derailments, the factories burning down and everything else going on in the world is not enough.

[pandemic-info]

Vaccines currently in development

(I did not create this list and I'm sorry I don't know the original OP who compiled it.)

These are all currently in development to come to market in the next 2 years. If just one really works it will be a game changer

MT-001 a novel protein component vaccine candidate, MT-001, based on a fragment of the SARS-CoV-2 spike protein that encompasses the receptor binding domain (RBD) | A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response - https://www.mdpi.com/2076-393X/11/4/832 Mice and hamsters immunized with a prime-boost regimen of MT-001 demonstrated extremely high anti-spike IgG titers, and remarkably this humoral response did not appreciably wane for up to 12 months following vaccination. Further, virus neutralization titers, including titers against variants such as Delta and Omicron BA.1, remained high without the requirement for subsequent boosting.

DCFHP a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. | A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110616/#MOESM3

ISM3312 a COVID-19 drug entirely designed by generative AI works by inhibiting a protein called 3CL protease — a critical factor in viral replication and a popular target for anti-COVID drugs. Unlike similar therapeutics, it works on a very broad spectrum — showing efficacy not only against all current COVID variants, but also coronaviruses other than SARS-CoV-2. As such, it may possess the ability to resist future mutations, providing a solution to drug-resistant strains. | ‘It’s perfect’: World’s first generative AI-designed COVID drug to start clinical trials https://www.thestar.com/news/canada/2023/02/23/its-perfect-worlds-first-generative-ai-designed-covid-drug-to-start-clinical-trials.html

BNT162b4, composed of a T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins that are highly conserved across a broad range of SARS-CoV-2 variants and will be evaluated in combination with the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine | Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-advance-next-generation-covid-19-vaccine

25F9 and 20A7 identified as two highly potent broadly neutralizing antibodies, making them promising prophylactic candidates against sarbecovirus infection |Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine – Science Translational Medicine – https://www.science.org/doi/10.1126/scitranslmed.adg7404

ChAd-SARS-CoV-2-BA.5-S, which encodes for a pre- fusion and surface-stabilized S protein of the BA.5 strain. | A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters https://www.biorxiv.org/content/10.1101/2023.05.04.539332v1

[snowyjay]

every person should be masked at all times within medical facilities. period. pandemic or not. why is this not treated as a normal fucking safety requirement/precaution like wearing gloves?

[sound-overlord]

not to be annoyed at ppl who are annoying but if a headline says 'a hundred million americans are exposed to HEART DISEASE bc of VACCINES' and then the subtitle is '2.8 % of ppl studied had elevated protein levels that are known to be heart disease risk factors' then the body of the text says 'we only looked at ppl with extremely stressful jobs' and you think covid vaccines are dangerous maybe you just cant fucking read

[seamsshark]

I mask everywhere and not only have I never had Covid, I haven’t been sick since mid January 2020.

It’s late July 2024 at time of writing

[thoughtportal]

Opinion Here’s how to get free Paxlovid as many times as you need it

When the public health emergency around covid-19 ended, vaccines and treatments became commercial products, meaning companies could charge for them as they do other pharmaceuticals. Paxlovid, the highly effective antiviral pill that can prevent covid from becoming severe, now has a list price of nearly $1,400 for a five-day treatment course.

Thanks to an innovative agreement between the Biden administration and the drug’s manufacturer, Pfizer, Americans can still access the medication free or at very low cost through a program called Paxcess. The problem is that too few people — including pharmacists — are aware of it.

I learned of Paxcess only after readers wrote that pharmacies were charging them hundreds of dollars — or even the full list price — to fill their Paxlovid prescription. This shouldn’t be happening. A representative from Pfizer, which runs the program, explained to me that patients on Medicare and Medicaid or who are uninsured should get free Paxlovid. They need to sign up by going to paxlovid.iassist.com or by calling 877-219-7225. “We wanted to make enrollment as easy and as quick as possible,” the representative said.

Indeed, the process is straightforward. I clicked through the web form myself, and there are only three sets of information required. Patients first enter their name, date of birth and address. They then input their prescriber’s name and address and select their insurance type.

All this should take less than five minutes and can be done at home or at the pharmacy. A physician or pharmacist can fill it out on behalf of the patient, too. Importantly, this form does not ask for medical history, proof of a positive coronavirus test, income verification, citizenship status or other potentially sensitive and time-consuming information.

But there is one key requirement people need to be aware of: Patients must have a prescription for Paxlovid to start the enrollment process. It is not possible to pre-enroll. (Though, in a sense, people on Medicare or Medicaid are already pre-enrolled.)

Once the questionnaire is complete, the website generates a voucher within seconds. People can print it or email it themselves, and then they can exchange it for a free course of Paxlovid at most pharmacies.

Pfizer’s representative tells me that more than 57,000 pharmacies are contracted to participate in this program, including major chain drugstores such as CVS and Walgreens and large retail chains such as Walmart, Kroger and Costco. For those unable to go in person, a mail-order option is available, too.

The program works a little differently for patients with commercial insurance. Some insurance plans already cover Paxlovid without a co-pay. Anyone who is told there will be a charge should sign up for Paxcess, which would further bring down their co-pay and might even cover the entire cost.

Several readers have attested that Paxcess’s process was fast and seamless. I was also glad to learn that there is basically no limit to the number of times someone could use it. A person who contracts the coronavirus three times in a year could access Paxlovid free or at low cost each time.

Unfortunately, readers informed me of one major glitch: Though the Paxcess voucher is honored when presented, some pharmacies are not offering the program proactively. As a result, many patients are still being charged high co-pays even if they could have gotten the medication at no cost.

This is incredibly frustrating. However, after interviewing multiple people involved in the process, including representatives of major pharmacy chains and Biden administration officials, I believe everyone is sincere in trying to make things right. As we saw in the early days of the coronavirus vaccine rollout, it’s hard to get a new program off the ground. Policies that look good on paper run into multiple barriers during implementation.

Those involved are actively identifying and addressing these problems. For instance, a Walgreens representative explained to me that in addition to educating pharmacists and pharmacy techs about the program, the company learned it also had to make system changes to account for a different workflow. Normally, when pharmacists process a prescription, they inform patients of the co-pay and dispense the medication. But with Paxlovid, the system needs to stop them if there is a co-pay, so they can prompt patients to sign up for Paxcess.

Here is where patients and consumers must take a proactive role. That might not feel fair; after all, if someone is ill, people expect that the system will work to help them. But that’s not our reality. While pharmacies work to fix their system glitches, patients need to be their own best advocates. That means signing up for Paxcess as soon as they receive a Paxlovid prescription and helping spread the word so that others can get the antiviral at little or no cost, too.

{source}

[angeltannis]

Every time I listen to Comalies XX I go “Maybe it’s grown on me by now” Every time I’m disappointed anew

[arogyaformulations]

Harnessing Innovation: The Role of Hand Sanitizers in Combatting Corona Virus

In the fight against the Corona virus, innovation plays a pivotal role in developing effective solutions. Hand sanitizers have emerged as a crucial tool in preventing the spread of the virus, offering convenient and accessible means of disinfection. This article explores the science behind hand sanitizers, highlighting their role in breaking the chain of transmission and protecting public health. Additionally, we delve into the manufacturing process of hand sanitizers, emphasizing the importance of quality and efficacy. By harnessing the power of innovation, we can bolster our defenses against the Corona virus and pave the way for a safer future.

[gumjrop]

The Weather

A study in Clinical Infectious Diseases reported “that the risk of developing symptomatic illness within 14 days was 5 times greater when contacts were exposed to an asymptomatic [COVID]-positive child in their household.” Nearly 11% of household contacts developed symptoms within 14 days of exposure. The study also found, during a 3-month follow-up, that 6 out of 77 asymptomatic children developed Long COVID. The likelihood of developing symptoms from asymptomatic exposure is higher than we might expect. Continue to spread awareness of asymptomatic spread and advocate for increased infection control measures at your local schools.

COVID wastewater levels are decreasing. As of 3/29/24, New Mexico is “Very High,” Arkansas and Kentucky are “High,” and the rest of the states are “Moderate” to “Low” levels of SARS-CoV-2 detected in wastewater. 

Wastewater levels continue to show a downward trend in the provisional data (gray shaded area) in all regions. The national wastewater levels are overall indicated as “Low.” While lower wastewater levels indicate decreased spread, it is important to continue to take precautions against infection. Holidays and spring breaks may bring people in closer proximity, so be sure to wear a mask to protect yourself and your community.

Wins

As we work to take more actions against the removal of vital public health measures, we remind you that you can still watch the recording of the People’s CDC press conference from March 13 and read the press release here. We would also like to remind you of the pre-proof of the People’s CDC External Review in the American Journal of Preventive Medicine Focus. The publication highlights the shortcomings of the CDC’s approach to public health and recommends a more equitable pandemic response.

News sources have published articles about the frustrations of people who continue to take COVID precautions. Time Magazine published an article presenting “both sides,” highlighting protest from people working with the CDC and concern from citizens and experts alike. While we are glad to see our voices be published in popular media, we are also saddened that “returning to normal” under economic and political pressure is so valued.

Treatments

Invyvid has received an FDA emergency use authorization for Pemgarda, a pre-exposure prophylaxis (PrEP) for people with immunocompromising conditions. Pemgarda is approved for people 12 and older with moderate to severe immunocompromise who are less likely to produce an adequate immune response to COVID vaccination alone. According to a press release from Invyvid, Pemgarda will release to market “imminently.”

Pre-exposure prophylaxis is commonly used for folks at high risk for exposure to HIV. As access to PrEP for HIV has been instrumental in keeping people safe, we hope that PrEP for COVID will be a useful tool for our community members with immune compromise. We also urge you to continue to wear high-quality masks and take other precautions to protect those most vulnerable.

Long COVID

People Magazine recently published an article highlighting an essay by Ziyad Al-Aly, physician and clinical epidemiologist, that pools data from several studies showing that COVID infection has lasting impacts on brain health. The review points out several impacts to cognitive functioning, including memory loss, spatial reasoning, and planning. Additionally, imaging studies have shown significant impact to brain tissue from inflammation, among other processes. The publication may be validating to those who experience lower cognitive function following COVID infection, including brain fog and memory dysfunction.

Take Action

We know that taking precautions–including masking, testing, and improving air quality–helps prevent the spread of airborne viral infection. Introducing more stringent precautions slowed outbreaks in the hematology ward of a hospital. The CDC recently released tips to improve ventilation. Help us urge the CDC to take other measures, including reinstating isolation periods. 

Additionally, the home Test to Treat program is ending in April 2024. The program provides un-or-underinsured adults with free COVID and flu tests. If a participant in the program tests positive, they can also receive free healthcare via telehealth services. Join us to help save the program that helps so many at-risk people!

[kushpluglegit]

Ozempic, Mounjaro and Wegovy available in stock

Follow us on telegram: https://t.me/WeightLossMedicines

[infinitycarehospital]

The experts at Infinity Care discuss some details of COVID-19

Corona has once again caused concern; after China and Japan, the new variant of Corona is spreading rapidly in India now. The coronavirus is a very subtle but effective virus. Coronavirus is 900 times smaller than human hair, but coronavirus infection is the first life-threatening virus to spread rapidly around the world.

The coronavirus belongs to a family of viruses whose infection can cause problems ranging from a cold to shortness of breath. This virus has never been seen before. The infection of this virus started in December 2019 in Wuhan, China. According to the WHO, fever, coughing, and shortness of breath are symptoms.

[inkbotkowalski]

mmmmm tasty tasty Paxlovid Mouth xP

[chandigarhayurved]

PREMATURE EJACULATION

WHAT IS PREMATURE EJACULATION ?

-  Premature ejaculation is a common sexual disorder in which a man ejaculates (releases semen) earlier than he or his partner desires during sexual activity. It often occurs with minimal sexual stimulation and can lead to distress or frustration. The specific duration that is considered "premature" can vary, but generally, if it happens consistently and causes distress, it may be a concern. It can have various causes, including psychological and physical factors, and can be treated through counseling, behavioral techniques, or medication, depending on the underlying causes.CAUSES OF PREMATURE EJACULATION :

Premature ejaculation can have various causes, which may include:

Psychological factors: Stress, anxiety, performance pressure, and relationship issues can contribute to premature ejaculation. These psychological factors can affect a person's ability to control their ejaculation.

Biological factors: Some men may have hypersensitive penile skin or an overactive ejaculatory reflex, which can make them more prone to premature ejaculation.

Hormonal imbalances: An imbalance in hormone levels, such as serotonin, can influence ejaculation control.

Medical conditions: Certain medical conditions, like erectile dysfunction, prostatitis, or thyroid problems, can contribute to premature ejaculation.

Medications: Some medications may have side effects that affect ejaculation, either by speeding it up or delaying it.

Lifestyle factors: Poor sexual habits, excessive alcohol or drug use, and lack of physical activity can also be contributing factors.

Inexperience: For some individuals, premature ejaculation may be a result of inexperience with sexual activity, and with time and practice, this issue may resolve.

PREMATURE EJACULATION IS CLASSIFIED INTO 2 CATEGORIES :

Primary (Lifelong): This type of condition has been seen almost every time since the beginning of sexual activity.

Secondary (Acquired): This type usually develops later in the stage and where previous sexual experiences did not have any problem.

SYMPTOMS OF PREMATURE EJACULATION :

The primary symptom of premature ejaculation is the inability to delay ejaculation during sexual activity, often leading to ejaculation occurring earlier than desired by the individual or their partner. Some common symptoms and characteristics associated with premature ejaculation include:

Ejaculation occurring within one to two minutes of penetration or even before penetration.

The inability to control when ejaculation happens, often with minimal sexual stimulation.

A persistent and recurrent pattern of early ejaculation that causes distress or dissatisfaction for either the individual or their partner.

Frustration, anxiety, or embarrassment related to sexual performance.

Avoidance of sexual intimacy or a reduced desire for sexual activity due to the fear of premature ejaculation.

DIAGNOSIS OF PREMATURE EJACULATION :

Medical History: The healthcare provider will take a detailed medical and sexual history, including questions about the frequency and duration of premature ejaculation, any underlying medical conditions, medications, and psychological factors that may contribute to the issue.

Physical Examination: A physical examination may be performed to rule out any physical conditions that could be causing or contributing to premature ejaculation.

Psychological Assessment: In some cases, a psychological evaluation may be conducted to assess factors such as anxiety, stress, or relationship problems that may be influencing premature ejaculation.

Evaluation of Sexual Function: Assessing overall sexual function, including erectile function, may be part of the evaluation to understand the broader context of the issue.

AYURVEDIC HERBS FOR PREMATURE EJACULATION TREATMENT :

Ashwagandha

Shilajit

Jayphal

Ginger & Honey

Amla

Shatavari

Yastimadhu

Safed Musli

Gokhshura Powder

Kaunch Powder

CAC TREATMENT FOR PREMATURE EJACULATION

PREMATURE EJACULATION CARE KIT

Chandigarh Ayurved Centre’s “Premature Ejaculation Care Kit” is purely herbal and authentic formulation. These medicines helps to pacify vata dosha  thus relieves associated symptoms also. The medicines have antioxidant and nerve stimulating properties which helps to strengthen nerves and rejuvenates the body thus provides excellent results in Premature Ejaculation condition. The kit contain:

Nerve Up Tablets

Active Plus Tablets

Triphala Guggulu

Men Power Plus Tablets

Rasayan Vati

1. Nerve up tablet:Nerve up tablet is a herbo-mineral tablet and is the purely ayurvedic formulation. CAC Nerve up tablets helps in balancing the Vata doshas. It reduces Kapha dosha, and acts as a nervine stimulant. It shows effective results in improving the central nervous system. It contains natural ingredients like shudha kuchala, shudha shilajeet,   praval pishti, shankh bhasma etc. These contain natural vatahar properties and helps in curing Vata diseases. It acts as CNS stimulant: speed up physical and mental processes. Works in Erectile dysfunction, Body weakness, and Insomnia Recommended Dosage: Take one tablet twice daily. 2. Active Plus Tablet: CAC active plus Tablet is a pure herbo-mineral formulation prepared from best quality of herbs. This tablet is best for person mental and physical health, also helps to boost up the immunity. The herbal ingredients present in these tablets are used to maintain person’s health and refreshes the mind and body. These tablets improves digestion, eliminates constipation, stress, nourishes brain,  acts as antioxidant, analgesic, anti-inflammatory, etc. Recommended Dosage: Take one tablet twice daily.

3. Triphla Guggulu: Triphala Guggulu Tablet has been used in ayurvedic medicine since ages. It is thought to support bowel health and aid digestion. As an antioxidant, it is used to detoxify the body and support the immune system. It is known for its antibacterial, antioxidant, antiviral abilities.  It is prescribed for a wide range of ailments like promoting oral health, treating fatigue and gastric distress, pneumonia, constipation, vaginal infections and most importantly boost the immune system. Recommended dosage: Recommended Dosage: Take one tablet twice daily. 4. Men Power Plus tablet: Mostly at one age men may suffer from low self-esteem and become negative. This also occurs because they are facing problems in their sexual life. There might be early ejaculation and erectile dysfunction. A feeling of inferiority also occurs and they feel hesitate to visit a doctor or discuss this problem. It also affects their relationship and leads to fighting, divorce, loss of self-confidence, the stress in their personal life. If a person has difficulty in having and keeping an erection more than 25% of the time, its a time for consultation. Ayurveda offers a great solution to this problem. Uses: Provide strength to the whole body and help to relieve erectile dysfunction naturally. All herbs are aphrodisiac, helps to increase stamina. The best source of male hormone precursors. Can be used by bodybuilders Relieve impotency Self-confidence and increase sperm count and sperm quality These herbs are antioxidant properties, the best supplement that works in anti-aging and provides strength. Reduce serum glucose levels Helps to relieve hypertension Reduces Infertility Recommended Dosage: Take one tablet twice daily. 5. Rasayan vati: CAC Rasayan vati is herbo-mineral ayurvedic formulation, which is 100% natural. Rasayan vati contains various herbs such as Aswagandha, Shilajeet, Amla, Kesar, Musali, Shatavar, Brahmi , Swarn Makshik Bhasam, Yashad Bhasam, Mukta pisti, Praval pisti, Jaiphal, Vang Bhasam, Dalchini, Javitri, Gokhru, Kaunch Beej, Saunth, Mirch, Pipli, Amla, Kesar, Manjith, Anant Mool, Brahmi, Musali, Swarn Vang, etc. These ingredients show antioxidant, aphrodisiac, anti-inflammatory, antipyretic, analgesic, immuno-modulator properties. Recommended Dosage – Take 1 tablet twice daily with normal water.